Macrolide Antibiotics Market By Drug Type (Azithromycin, Erythromycin, Others), By Route of Administration (Oral, Parenteral, Others), By Indication (Respiratory Tract Infections, Skin Infections, Sexually Transmitted Infections, Gastrointestinal Infections, Others), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2023-2032

Macrolide Antibiotics Market

The macrolide antibiotics market is likely to experience a significant growth rate of 2.3% from 2023-2032 owing to increasing market demand from pharmaceuticals sector –  

Macrolide antibiotics are the products obtained naturally, which act by inhibiting the synthesis of bacterial protein, thereby limiting the bacterial growth and spread of bacterial infections. Macrolides are used for the treatment of illnesses brought on by gram-positive bacteria. Atypical mycobacterial infections, H. pylori, skin, soft tissue, respiratory, sexually transmitted, and other infections can be successfully treated with macrolides.   

Key factors driving the growth of the macrolide antibiotics market are attributed to the rise in incidences of bacterial infections, availability of generic medications and significant demand for macrolides from emerging countries. There is a huge demand for macrolide antibiotics in the developing region owing to high incidences of microbial infections in this region. In addition, emerging countries often have high incidences of infectious diseases due to factors such as poor sanitation, limited access to clean water, and overcrowded living conditions. These infections can be treated with macrolide antibiotics which propels its demand in the healthcare sector.  

In addition, macrolide antibiotics are available in generic form with further contributes to the rising demand for these medications. Generic products are easily available at a lower price as compared to other branded medications which can be easily accessible by the people in poor income countries. This affordability factor drives the demand for generic macrolide drugs and expands the market size. 

Furthermore, development of novel macrolide antibiotics is anticipated to drive the market growth during the forecast period. Key players are investing on a large scale to develop new products that are effective against antibiotic resistance bacteria, as antimicrobial resistance is one of the major global threats to human beings and the healthcare industry. For instance, in January 2020, Merck announced the U.S. Food and Drug Administration (FDA) approval of New Drug Application (NDA) for DIFICID (fidaxomicin) tablets, for the treatment of Clostridioides difficile-associated diarrhea (CDAD) in children aged six months and older. Such development of novel therapeutics is anticipated to propel the market growth in coming years.  

Furthermore, the macrolide antibiotics market is expected to experience significant growth opportunities in developing regions over the next few years. The developing regions are working towards improving their healthcare infrastructure for which they need to set up and expand medical facilities, such as hospitals, clinics and outpatient care centers. This growth in medical facilities creates a need for medical gases, which are needed for patient care and for a variety of medical procedures.  

The macrolide antibiotics market is segmented on the basis of drug type, route or administration, indication, distribution channel, and region. On the basis of drug type, the market is segmented into erythromycin, azithromycin, and others. On the basis of route of administration, the market is classified into oral, parenteral, and others. By indication, the market is segmented into respiratory tract infections, skin infections, sexually transmitted infections, gastrointestinal infections, and others. On the basis of distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online providers.  

By region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).  

The key players profiled in the study include Abbott Laboratories, Pfizer Inc., Alkem Laboratories Ltd., Merck & Co., Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Limited, Centurion Healthcare Private Limited, Wellona Pharma, Bristol Laboratories Ltd., and Crescent Pharma Limited. The players in the market have been actively engaged in the adoption of various strategies such as product approval and product launch to remain competitive and gain an advantage over the competitors in the market.  

For instance, in March 2023, Zydus Lifesciences Limited received the U.S. Food and Drug Administration (USFDA) approval for Erythromycin Tablets USP, 250 mg and 500 mg. It is an antibacterial product and is used to prevent and treat infections in many different parts of the body, including respiratory tract infections, skin infections, diphtheria, intestinal amebiasis, acute pelvic inflammatory disease, Legionnaire's disease and pertussis. 

Key Market Insights 

By route of administration, the oral segment dominated the global market and is expected to be the fastest-growing segment during the forecast period. 

By indication, the respiratory tract infections segment dominated the market in 2022 and is anticipated to be the fastest growing segment during the forecast period.  

By distribution channel, the drug stores & retail pharmacies segment dominated the market in 2022, whereas the online providers segment is anticipated to grow at a fastest rate during the forecast period.  

Based on region, Asia-Pacific garnered the largest revenue share in 2022 and is anticipated to grow at the highest CAGR during the forecast period. 

Overview

The macrolide antibiotics market was valued at $5.6 billion in 2022 and is estimated to reach $7.0 billion by 2032, exhibiting a CAGR of 2.3% from 2023 to 2032. Macrolides are a class of antibiotics, used to treat and manage bacterial infections. These antibiotic compounds have a macrocyclic lactone ring attached with deoxy sugars. Erythromycin was the first macrolide antibiotic developed in 1952 and was used in the treatment of infections in patients allergic to penicillin and also in the case of penicillin resistant infections. Other macrolide antibiotics include roxithromycin, clarithromycin, telithromycin, azithromycin, fidaxomicin and others. The FDA has approved the use of these antibiotics in the treatment of various bacterial infections, which increases their demand in the market.  

Macrolide antibiotics act by inhibiting bacterial protein synthesis. These compounds bind to the bacterial 50 S ribosomal subunit, causing the cessation of bacterial protein synthesis. After binding, the drug prevents the translation of mRNA, by inhibiting the enzyme peptidyl transferase from adding the subsequent amino acid attached to the tRNA. Erythromycin is the most used antibiotic, followed by azithromycin and clarithromycin. These antibiotics are active against many strains of bacteria such as streptococci, staphylococci, clostridia, corynebacteria, listeria, haemoplhillus, and others. Erythromycin has a narrow spectrum of activity with action against gram-positive and few gram-negative bacteria. On the other hand, clarithromycin and azithromycin are active against gram-negative bacteria such as helicobacter pylori, taxoplasma gondii and others. 

Rise in incidences of bacterial infections around the globe is the major factor driving the growth of the macrolide antibiotics market. There is a significant prevalence of bacterial diseases such as skin infections, respiratory tract infections, sextually transmitted bacterial infection, and others. For instance, according to the WHO, there were an estimated 82.4 million new gonorrhoea infections among adults in 2020. Gonorrhoea is a common sexually transmitted infection having the highest incidence among sex workers, transgender women and adolescents. Thus, rise in incidences of such infections boost the demand for macrolide antibiotics, which contributes to the market growth.  

However, rise in antimicrobial resistance among the bacterial species causes hindrance to the market growth. Emergence of macrolide resistant bacteria causes difficulty in treatment of severe infections, which may lead to the death of the patient, increase hospital stay, and increase the cost and expenses related to treatment. As the number of infections caused by macrolide resistant bacteria increases, drugs become ineffective for treatment and thus, there is a reduction in use of available macrolide medications. . This may hinder the growth of the macrolide antibiotics market.  

However, a rise in antimicrobial resistance for macrolide class of drug is expected to offer lucrative opportunities for market growth during the forecast period. As bacteria are resistant to the available macrolide antibiotics, there is rise in demand for development of new novel macrolide antibiotics that may help overcome the resistance and thus, are effective in the treatment of severe bacterial infections. This increases R&D activities related to the macrolides and thus, is expected to offer lucrative opportunities for market growth in the coming years. 

The macrolide antibiotics market is segmented on the basis of drug type, route or administration, indication, distribution channel, and region. On the basis of drug type, the market is segmented into azithromycin, erythromycin, and others. On the basis of route of administration, the market is classified into oral, parenteral, and others. By indication, the market is segmented into respiratory tract infections, skin infections, sexually transmitted infections, gastrointestinal infections, and others. On the basis of distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. 

By region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of AsiaPacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA). Major players that operate in the market include Abbott Laboratories, Pfizer Inc., Alkem Laboratories Ltd., Merck & Co., Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Limited, Centurion Healthcare Private Limited, Wellona Pharma, Bristol Laboratories Ltd., and Crescent Pharma Limited. 

Key Benefits for Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the macrolide antibiotics market analysis from 2022 to 2032 to identify the prevailing macrolide antibiotics market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the macrolide antibiotics market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global macrolide antibiotics market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

● Quarterly Update and* (only available with a corporate license, on listed price)

● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

● Free Upcoming Version on the Purchase of Five and Enterprise User License.

● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)

● Free data Pack on the Five and Enterprise User License. (Excel version of the report)

● Free Updated report if the report is 6-12 months old or older.

● 24-hour priority response*

● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

● Regulatory Guidelines

● Additional company profiles with specific to client's interest

● Additional country or region analysis- market size and forecast

● Expanded list for Company Profiles

● Historic market data

● Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

○ Abbott Laboratorie

Scope of Macrolide Antibiotics Market Report

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

2.1. CXO Perspective

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. Moderate bargaining power of suppliers

3.3.2. Low threat of new entrants

3.3.3. Low threat of substitutes

3.3.4. Low intensity of rivalry

3.3.5. Low bargaining power of buyers

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Rise in incidences of bacterial infections

3.4.1.2. Availability of generic medications

3.4.1.3. Significant demand for macrolides from emerging countries

3.4.2. Restraints

3.4.2.1. Rise in antimicrobial resistance

3.4.2.2. Side effects associated with macrolide antibiotics

3.4.3. Opportunities

3.4.3.1. Rise in investments in research and development activities

4.1. Overview

4.1.1. Market size and forecast

4.2. Azithromycin

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Erythromycin

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

4.4. Others

4.4.1. Key market trends, growth factors and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market share analysis by country

5.1. Overview

5.1.1. Market size and forecast

5.2. Oral

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Parenteral

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

5.4. Others

5.4.1. Key market trends, growth factors and opportunities

5.4.2. Market size and forecast, by region

5.4.3. Market share analysis by country

6.1. Overview

6.1.1. Market size and forecast

6.2. Respiratory Tract Infections

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Skin Infections

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

6.4. Sexually Transmitted Infections

6.4.1. Key market trends, growth factors and opportunities

6.4.2. Market size and forecast, by region

6.4.3. Market share analysis by country

6.5. Gastrointestinal Infections

6.5.1. Key market trends, growth factors and opportunities

6.5.2. Market size and forecast, by region

6.5.3. Market share analysis by country

6.6. Others

6.6.1. Key market trends, growth factors and opportunities

6.6.2. Market size and forecast, by region

6.6.3. Market share analysis by country

7.1. Overview

7.1.1. Market size and forecast

7.2. Hospital Pharmacies

7.2.1. Key market trends, growth factors and opportunities

7.2.2. Market size and forecast, by region

7.2.3. Market share analysis by country

7.3. Drug Stores and Retail Pharmacies

7.3.1. Key market trends, growth factors and opportunities

7.3.2. Market size and forecast, by region

7.3.3. Market share analysis by country

7.4. Online Providers

7.4.1. Key market trends, growth factors and opportunities

7.4.2. Market size and forecast, by region

7.4.3. Market share analysis by country

8.1. Overview

8.1.1. Market size and forecast By Region

8.2. North America

8.2.1. Key market trends, growth factors and opportunities

8.2.2. Market size and forecast, by Drug Type

8.2.3. Market size and forecast, by Route of Administration

8.2.4. Market size and forecast, by Indication

8.2.5. Market size and forecast, by Distribution Channel

8.2.6. Market size and forecast, by country

8.2.6.1. U.S.

8.2.6.1.1. Market size and forecast, by Drug Type

8.2.6.1.2. Market size and forecast, by Route of Administration

8.2.6.1.3. Market size and forecast, by Indication

8.2.6.1.4. Market size and forecast, by Distribution Channel

8.2.6.2. Canada

8.2.6.2.1. Market size and forecast, by Drug Type

8.2.6.2.2. Market size and forecast, by Route of Administration

8.2.6.2.3. Market size and forecast, by Indication

8.2.6.2.4. Market size and forecast, by Distribution Channel

8.2.6.3. Mexico

8.2.6.3.1. Market size and forecast, by Drug Type

8.2.6.3.2. Market size and forecast, by Route of Administration

8.2.6.3.3. Market size and forecast, by Indication

8.2.6.3.4. Market size and forecast, by Distribution Channel

8.3. Europe

8.3.1. Key market trends, growth factors and opportunities

8.3.2. Market size and forecast, by Drug Type

8.3.3. Market size and forecast, by Route of Administration

8.3.4. Market size and forecast, by Indication

8.3.5. Market size and forecast, by Distribution Channel

8.3.6. Market size and forecast, by country

8.3.6.1. Germany

8.3.6.1.1. Market size and forecast, by Drug Type

8.3.6.1.2. Market size and forecast, by Route of Administration

8.3.6.1.3. Market size and forecast, by Indication

8.3.6.1.4. Market size and forecast, by Distribution Channel

8.3.6.2. France

8.3.6.2.1. Market size and forecast, by Drug Type

8.3.6.2.2. Market size and forecast, by Route of Administration

8.3.6.2.3. Market size and forecast, by Indication

8.3.6.2.4. Market size and forecast, by Distribution Channel

8.3.6.3. UK

8.3.6.3.1. Market size and forecast, by Drug Type

8.3.6.3.2. Market size and forecast, by Route of Administration

8.3.6.3.3. Market size and forecast, by Indication

8.3.6.3.4. Market size and forecast, by Distribution Channel

8.3.6.4. Italy

8.3.6.4.1. Market size and forecast, by Drug Type

8.3.6.4.2. Market size and forecast, by Route of Administration

8.3.6.4.3. Market size and forecast, by Indication

8.3.6.4.4. Market size and forecast, by Distribution Channel

8.3.6.5. Spain

8.3.6.5.1. Market size and forecast, by Drug Type

8.3.6.5.2. Market size and forecast, by Route of Administration

8.3.6.5.3. Market size and forecast, by Indication

8.3.6.5.4. Market size and forecast, by Distribution Channel

8.3.6.6. Rest of Europe

8.3.6.6.1. Market size and forecast, by Drug Type

8.3.6.6.2. Market size and forecast, by Route of Administration

8.3.6.6.3. Market size and forecast, by Indication

8.3.6.6.4. Market size and forecast, by Distribution Channel

8.4. Asia-Pacific

8.4.1. Key market trends, growth factors and opportunities

8.4.2. Market size and forecast, by Drug Type

8.4.3. Market size and forecast, by Route of Administration

8.4.4. Market size and forecast, by Indication

8.4.5. Market size and forecast, by Distribution Channel

8.4.6. Market size and forecast, by country

8.4.6.1. Japan

8.4.6.1.1. Market size and forecast, by Drug Type

8.4.6.1.2. Market size and forecast, by Route of Administration

8.4.6.1.3. Market size and forecast, by Indication

8.4.6.1.4. Market size and forecast, by Distribution Channel

8.4.6.2. China

8.4.6.2.1. Market size and forecast, by Drug Type

8.4.6.2.2. Market size and forecast, by Route of Administration

8.4.6.2.3. Market size and forecast, by Indication

8.4.6.2.4. Market size and forecast, by Distribution Channel

8.4.6.3. India

8.4.6.3.1. Market size and forecast, by Drug Type

8.4.6.3.2. Market size and forecast, by Route of Administration

8.4.6.3.3. Market size and forecast, by Indication

8.4.6.3.4. Market size and forecast, by Distribution Channel

8.4.6.4. Australia

8.4.6.4.1. Market size and forecast, by Drug Type

8.4.6.4.2. Market size and forecast, by Route of Administration

8.4.6.4.3. Market size and forecast, by Indication

8.4.6.4.4. Market size and forecast, by Distribution Channel

8.4.6.5. South Korea

8.4.6.5.1. Market size and forecast, by Drug Type

8.4.6.5.2. Market size and forecast, by Route of Administration

8.4.6.5.3. Market size and forecast, by Indication

8.4.6.5.4. Market size and forecast, by Distribution Channel

8.4.6.6. Rest of Asia-Pacific

8.4.6.6.1. Market size and forecast, by Drug Type

8.4.6.6.2. Market size and forecast, by Route of Administration

8.4.6.6.3. Market size and forecast, by Indication

8.4.6.6.4. Market size and forecast, by Distribution Channel

8.5. LAMEA

8.5.1. Key market trends, growth factors and opportunities

8.5.2. Market size and forecast, by Drug Type

8.5.3. Market size and forecast, by Route of Administration

8.5.4. Market size and forecast, by Indication

8.5.5. Market size and forecast, by Distribution Channel

8.5.6. Market size and forecast, by country

8.5.6.1. Brazil

8.5.6.1.1. Market size and forecast, by Drug Type

8.5.6.1.2. Market size and forecast, by Route of Administration

8.5.6.1.3. Market size and forecast, by Indication

8.5.6.1.4. Market size and forecast, by Distribution Channel

8.5.6.2. Saudi Arabia

8.5.6.2.1. Market size and forecast, by Drug Type

8.5.6.2.2. Market size and forecast, by Route of Administration

8.5.6.2.3. Market size and forecast, by Indication

8.5.6.2.4. Market size and forecast, by Distribution Channel

8.5.6.3. South Africa

8.5.6.3.1. Market size and forecast, by Drug Type

8.5.6.3.2. Market size and forecast, by Route of Administration

8.5.6.3.3. Market size and forecast, by Indication

8.5.6.3.4. Market size and forecast, by Distribution Channel

8.5.6.4. Rest of LAMEA

8.5.6.4.1. Market size and forecast, by Drug Type

8.5.6.4.2. Market size and forecast, by Route of Administration

8.5.6.4.3. Market size and forecast, by Indication

8.5.6.4.4. Market size and forecast, by Distribution Channel

9.1. Introduction

9.2. Top winning strategies

9.3. Product mapping of top 10 player

9.4. Competitive dashboard

9.5. Competitive heatmap

9.6. Top player positioning, 2022

10.1. Abbott Laboratories

10.1.1. Company overview

10.1.2. Key executives

10.1.3. Company snapshot

10.1.4. Operating business segments

10.1.5. Product portfolio

10.1.6. Business performance

10.2. Pfizer Inc.

10.2.1. Company overview

10.2.2. Key executives

10.2.3. Company snapshot

10.2.4. Operating business segments

10.2.5. Product portfolio

10.2.6. Business performance

10.3. Alkem Laboratories Ltd.

10.3.1. Company overview

10.3.2. Key executives

10.3.3. Company snapshot

10.3.4. Operating business segments

10.3.5. Product portfolio

10.3.6. Business performance

10.4. Sun Pharmaceutical Industries Limited

10.4.1. Company overview

10.4.2. Key executives

10.4.3. Company snapshot

10.4.4. Operating business segments

10.4.5. Product portfolio

10.4.6. Business performance

10.5. Teva Pharmaceutical Industries Limited

10.5.1. Company overview

10.5.2. Key executives

10.5.3. Company snapshot

10.5.4. Operating business segments

10.5.5. Product portfolio

10.5.6. Business performance

10.5.7. Key strategic moves and developments

10.6. Wellona Pharma Private Limited.

10.6.1. Company overview

10.6.2. Key executives

10.6.3. Company snapshot

10.6.4. Operating business segments

10.6.5. Product portfolio

10.7. Bristol Laboratories Ltd.

10.7.1. Company overview

10.7.2. Key executives

10.7.3. Company snapshot

10.7.4. Operating business segments

10.7.5. Product portfolio

10.8. Crescent Pharma Limited

10.8.1. Company overview

10.8.2. Key executives

10.8.3. Company snapshot

10.8.4. Operating business segments

10.8.5. Product portfolio

10.9. Merck & Co., Inc.

10.9.1. Company overview

10.9.2. Key executives

10.9.3. Company snapshot

10.9.4. Operating business segments

10.9.5. Product portfolio

10.9.6. Business performance

10.9.7. Key strategic moves and developments

10.10. Zydus Lifesciences Limited

10.10.1. Company overview

10.10.2. Key executives

10.10.3. Company snapshot

10.10.4. Operating business segments

10.10.5. Product portfolio

10.10.6. Business performance

10.10.7. Key strategic moves and development

LIST OF TABLES

TABLE 01. GLOBAL MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 02. MACROLIDE ANTIBIOTICS MARKET FOR AZITHROMYCIN, BY REGION, 2022-2032 ($MILLION)

TABLE 03. MACROLIDE ANTIBIOTICS MARKET FOR ERYTHROMYCIN, BY REGION, 2022-2032 ($MILLION)

TABLE 04. MACROLIDE ANTIBIOTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 05. GLOBAL MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 06. MACROLIDE ANTIBIOTICS MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)

TABLE 07. MACROLIDE ANTIBIOTICS MARKET FOR PARENTERAL, BY REGION, 2022-2032 ($MILLION)

TABLE 08. MACROLIDE ANTIBIOTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 09. GLOBAL MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 10. MACROLIDE ANTIBIOTICS MARKET FOR RESPIRATORY TRACT INFECTIONS, BY REGION, 2022-2032 ($MILLION)

TABLE 11. MACROLIDE ANTIBIOTICS MARKET FOR SKIN INFECTIONS, BY REGION, 2022-2032 ($MILLION)

TABLE 12. MACROLIDE ANTIBIOTICS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY REGION, 2022-2032 ($MILLION)

TABLE 13. MACROLIDE ANTIBIOTICS MARKET FOR GASTROINTESTINAL INFECTIONS, BY REGION, 2022-2032 ($MILLION)

TABLE 14. MACROLIDE ANTIBIOTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 15. GLOBAL MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 16. MACROLIDE ANTIBIOTICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)

TABLE 17. MACROLIDE ANTIBIOTICS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)

TABLE 18. MACROLIDE ANTIBIOTICS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)

TABLE 19. MACROLIDE ANTIBIOTICS MARKET, BY REGION, 2022-2032 ($MILLION)

TABLE 20. NORTH AMERICA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 21. NORTH AMERICA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 22. NORTH AMERICA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 23. NORTH AMERICA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 24. NORTH AMERICA MACROLIDE ANTIBIOTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 25. U.S. MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 26. U.S. MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 27. U.S. MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 28. U.S. MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 29. CANADA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 30. CANADA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 31. CANADA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 32. CANADA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 33. MEXICO MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 34. MEXICO MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 35. MEXICO MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 36. MEXICO MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 37. EUROPE MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 38. EUROPE MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 39. EUROPE MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 40. EUROPE MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 41. EUROPE MACROLIDE ANTIBIOTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 42. GERMANY MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 43. GERMANY MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 44. GERMANY MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 45. GERMANY MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 46. FRANCE MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 47. FRANCE MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 48. FRANCE MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 49. FRANCE MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 50. UK MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 51. UK MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 52. UK MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 53. UK MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 54. ITALY MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 55. ITALY MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 56. ITALY MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 57. ITALY MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 58. SPAIN MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 59. SPAIN MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 60. SPAIN MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 61. SPAIN MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 62. REST OF EUROPE MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 63. REST OF EUROPE MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 64. REST OF EUROPE MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 65. REST OF EUROPE MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 66. ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 67. ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 68. ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 69. ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 70. ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 71. JAPAN MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 72. JAPAN MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 73. JAPAN MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 74. JAPAN MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 75. CHINA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 76. CHINA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 77. CHINA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 78. CHINA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 79. INDIA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 80. INDIA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 81. INDIA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 82. INDIA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 83. AUSTRALIA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 84. AUSTRALIA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 85. AUSTRALIA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 86. AUSTRALIA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 87. SOUTH KOREA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 88. SOUTH KOREA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 89. SOUTH KOREA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 90. SOUTH KOREA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 91. REST OF ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 92. REST OF ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 93. REST OF ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 94. REST OF ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 95. LAMEA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 96. LAMEA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 97. LAMEA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 98. LAMEA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 99. LAMEA MACROLIDE ANTIBIOTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 100. BRAZIL MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 101. BRAZIL MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 102. BRAZIL MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 103. BRAZIL MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 104. SAUDI ARABIA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 105. SAUDI ARABIA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 106. SAUDI ARABIA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 107. SAUDI ARABIA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 108. SOUTH AFRICA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 109. SOUTH AFRICA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 110. SOUTH AFRICA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 111. SOUTH AFRICA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 112. REST OF LAMEA MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)

TABLE 113. REST OF LAMEA MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)

TABLE 114. REST OF LAMEA MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022-2032 ($MILLION)

TABLE 115. REST OF LAMEA MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 116. ABBOTT LABORATORIES: KEY EXECUTIVES

TABLE 117. ABBOTT LABORATORIES: COMPANY SNAPSHOT

TABLE 118. ABBOTT LABORATORIES: PRODUCT SEGMENTS

TABLE 119. ABBOTT LABORATORIES: PRODUCT PORTFOLIO

TABLE 120. PFIZER INC.: KEY EXECUTIVES

TABLE 121. PFIZER INC.: COMPANY SNAPSHOT

TABLE 122. PFIZER INC.: PRODUCT SEGMENTS

TABLE 123. PFIZER INC.: PRODUCT PORTFOLIO

TABLE 124. ALKEM LABORATORIES LTD.: KEY EXECUTIVES

TABLE 125. ALKEM LABORATORIES LTD.: COMPANY SNAPSHOT

TABLE 126. ALKEM LABORATORIES LTD.: PRODUCT SEGMENTS

TABLE 127. ALKEM LABORATORIES LTD.: PRODUCT PORTFOLIO

TABLE 128. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES

TABLE 129. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT

TABLE 130. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS

TABLE 131. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO

TABLE 132. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES

TABLE 133. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT

TABLE 134. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS

TABLE 135. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO

TABLE 136. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES

TABLE 137. WELLONA PHARMA PRIVATE LIMITED.: KEY EXECUTIVES

TABLE 138. WELLONA PHARMA PRIVATE LIMITED.: COMPANY SNAPSHOT

TABLE 139. WELLONA PHARMA PRIVATE LIMITED.: PRODUCT SEGMENTS

TABLE 140. WELLONA PHARMA PRIVATE LIMITED.: PRODUCT PORTFOLIO

TABLE 141. BRISTOL LABORATORIES LTD.: KEY EXECUTIVES

TABLE 142. BRISTOL LABORATORIES LTD.: COMPANY SNAPSHOT

TABLE 143. BRISTOL LABORATORIES LTD.: PRODUCT SEGMENTS

TABLE 144. BRISTOL LABORATORIES LTD.: PRODUCT PORTFOLIO

TABLE 145. CRESCENT PHARMA LIMITED: KEY EXECUTIVES

TABLE 146. CRESCENT PHARMA LIMITED: COMPANY SNAPSHOT

TABLE 147. CRESCENT PHARMA LIMITED: PRODUCT SEGMENTS

TABLE 148. CRESCENT PHARMA LIMITED: PRODUCT PORTFOLIO

TABLE 149. MERCK & CO., INC.: KEY EXECUTIVES

TABLE 150. MERCK & CO., INC.: COMPANY SNAPSHOT

TABLE 151. MERCK & CO., INC.: PRODUCT SEGMENTS

TABLE 152. MERCK & CO., INC.: PRODUCT PORTFOLIO

TABLE 153. MERCK & CO., INC.: KEY STRATERGIES

TABLE 154. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES

TABLE 155. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT

TABLE 156. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS

TABLE 157. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO

TABLE 158. ZYDUS LIFESCIENCES LIMITED: KEY STRATERGIES LIST OF FIGURES

FIGURE 01. MACROLIDE ANTIBIOTICS MARKET, 2022-2032

FIGURE 02. SEGMENTATION OF MACROLIDE ANTIBIOTICS MARKET,2022-2032

FIGURE 03. TOP IMPACTING FACTORS IN MACROLIDE ANTIBIOTICS MARKET (2022 TO 2032)

FIGURE 04. TOP INVESTMENT POCKETS IN MACROLIDE ANTIBIOTICS MARKET (2023-2032)

FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS

FIGURE 06. LOW THREAT OF NEW ENTRANTS

FIGURE 07. LOW THREAT OF SUBSTITUTES

FIGURE 08. LOW INTENSITY OF RIVALRY

FIGURE 09. LOW BARGAINING POWER OF BUYERS

FIGURE 10. GLOBAL MACROLIDE ANTIBIOTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 11. MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE, 2022 AND 2032(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR AZITHROMYCIN, BY COUNTRY 2022 AND 2032(%)

FIGURE 13. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR ERYTHROMYCIN, BY COUNTRY 2022 AND 2032(%)

FIGURE 14. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 15. MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022 AND 2032(%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR ORAL, BY COUNTRY 2022 AND 2032(%)

FIGURE 17. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR PARENTERAL, BY COUNTRY 2022 AND 2032(%)

FIGURE 18. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 19. MACROLIDE ANTIBIOTICS MARKET, BY INDICATION, 2022 AND 2032(%)

FIGURE 20. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR RESPIRATORY TRACT INFECTIONS, BY COUNTRY 2022 AND 2032(%)

FIGURE 21. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR SKIN INFECTIONS, BY COUNTRY 2022 AND 2032(%)

FIGURE 22. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY COUNTRY 2022 AND 2032(%)

FIGURE 23. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR GASTROINTESTINAL INFECTIONS, BY COUNTRY 2022 AND 2032(%)

FIGURE 24. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 25. MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)

FIGURE 26. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 27. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 28. COMPARATIVE SHARE ANALYSIS OF MACROLIDE ANTIBIOTICS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 29. MACROLIDE ANTIBIOTICS MARKET BY REGION, 2022 AND 2032(%)

FIGURE 30. U.S. MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)

FIGURE 31. CANADA MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)

FIGURE 32. MEXICO MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)

FIGURE 33. GERMANY MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)

FIGURE 34. FRANCE MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)

FIGURE 35. UK MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)

FIGURE 36. ITALY MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)

FIGURE 37. SPAIN MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)

FIGURE 38. REST OF EUROPE MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)

FIGURE 39. JAPAN MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)

FIGURE 40. CHINA MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)

FIGURE 41. INDIA MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)

FIGURE 42. AUSTRALIA MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)

FIGURE 43. SOUTH KOREA MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)

FIGURE 44. REST OF ASIA-PACIFIC MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)

FIGURE 45. BRAZIL MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)

FIGURE 46. SAUDI ARABIA MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)

FIGURE 47. SOUTH AFRICA MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)

FIGURE 48. REST OF LAMEA MACROLIDE ANTIBIOTICS MARKET, 2022-2032 ($MILLION)

FIGURE 49. TOP WINNING STRATEGIES, BY YEAR (2020-2023)

FIGURE 50. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)

FIGURE 51. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)

FIGURE 52. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 53. COMPETITIVE DASHBOARD

FIGURE 54. COMPETITIVE HEATMAP: MACROLIDE ANTIBIOTICS MARKET

FIGURE 55. TOP PLAYER POSITIONING, 2022

FIGURE 56. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)

FIGURE 57. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 58. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 59. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 60. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 61. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 62. ALKEM LABORATORIES LTD.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 63. ALKEM LABORATORIES LTD.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 64. SUN PHARMACEUTICAL INDUSTRIES LIMITED: SALES REVENUE, 2020-2022 ($MILLION)

FIGURE 65. SUN PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 66. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 67. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 68. MERCK & CO., INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 69. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 70. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 71. ZYDUS LIFESCIENCES LIMITED: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 72. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 73. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY REGION, 2022 (%